114亿美元交易背后的野心,没换来股价上涨

36氪
Oct 24

文|胡香赟编辑|海若镜10月以来,创新药股市出现下滑走势,就在行业都调侃着“再来个大交易提振下信心”时,“大交易”真的来了。10月22日,信达生物宣布与武田制药达成总价114亿美元的授权合作,包括12亿美元首付款和102亿美元的潜在里程碑付款,其中,首付款中含有武田制药溢价20%入股信达生物的1亿美元,这笔钱将以8:2的比例用于全球管线研发和企业运营。未来,如果交易产品成功上市,信达生物还将按比例...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10